VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+8.21%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$214M
AUM Growth
+$9.71M
(+4.8%)
Cap. Flow
+$1.5M
Cap. Flow
% of AUM
0.7%
Top 10 Holdings %
Top 10 Hldgs %
6.68%
Holding
490
New
42
Increased
186
Reduced
165
Closed
36
Top Buys
| 1 |
OCCI
OFS Credit Co
OCCI
|
$2.06M |
| 2 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
$1.96M |
| 3 |
Applovin
APP
|
$1.49M |
| 4 |
Constellation Energy
CEG
|
$1.32M |
| 5 |
ECC
Eagle Point Credit Co
ECC
|
$1.26M |
Top Sells
| 1 |
OXLC
Oxford Lane Capital
OXLC
|
$1.49M |
| 2 |
Gen Digital
GEN
|
$1.01M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$1M |
| 4 |
Adobe
ADBE
|
$989K |
| 5 |
Steris
STE
|
$907K |
Sector Composition
| 1 | Financials | 28.16% |
| 2 | Healthcare | 18.37% |
| 3 | Technology | 14.33% |
| 4 | Industrials | 8.16% |
| 5 | Consumer Discretionary | 6.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Applied Therapeutics
APLT
$68.2M
| $149K | 0.07% |
17,524
+314
| +2% | +$2.67K |
|
|
CNTA
327
Centessa Pharmaceuticals
CNTA
$2.11B
| $148K | 0.07% |
9,285
+169
| +2% | +$2.7K |
|
328
Coterra Energy
CTRA
$18.3B
| $145K | 0.07% |
6,073
-30,303
| -83% | -$726K |
|
329
Sibanye-Stillwater
SBSW
$6.08B
| $145K | 0.07% |
35,193
-4,743
| -12% | -$19.5K |
|
330
Vaxcyte
PCVX
$4.29B
| $142K | 0.07% |
1,244
+21
| +2% | +$2.4K |
|
331
APA Corp
APA
$8.14B
| $141K | 0.07% |
5,770
+407
| +8% | +$9.96K |
|
332
Devon Energy
DVN
$22.1B
| $139K | 0.06% |
3,550
-186
| -5% | -$7.28K |
|
333
Biohaven
BHVN
$1.68B
| $138K | 0.06% |
2,760
+50
| +2% | +$2.5K |
|
334
Arcellx
ACLX
$4.03B
| $138K | 0.06% |
1,651
+28
| +2% | +$2.34K |
|
335
Edgewise Therapeutics
EWTX
$1.64B
| $137K | 0.06% |
5,145
+91
| +2% | +$2.43K |
|
336
Cassava Sciences
SAVA
$104M
| $136K | 0.06% |
4,634
+83
| +2% | +$2.44K |
|
337
Nuveen Churchill Direct Lending
NCDL
$788M
| $135K | 0.06% |
+7,737
| New | +$135K |
|
338
Berry Corp
BRY
$249M
| $134K | 0.06% |
26,127
+2,940
| +13% | +$15.1K |
|
339
Ovintiv
OVV
$10.6B
| $134K | 0.06% |
3,503
-26
| -0.7% | -$996 |
|
340
Praxis Precision Medicines
PRAX
$986M
| $132K | 0.06% |
2,297
+37
| +2% | +$2.13K |
|
|
VRN
341
DELISTED
Veren
VRN
| $131K | 0.06% |
21,374
-1,579
| -7% | -$9.71K |
|
342
AnaptysBio
ANAB
$613M
| $127K | 0.06% |
3,797
+64
| +2% | +$2.14K |
|
343
Zymeworks
ZYME
$1.14B
| $127K | 0.06% |
10,114
+177
| +2% | +$2.22K |
|
344
Apogee Therapeutics
APGE
$2.26B
| $126K | 0.06% |
2,138
+39
| +2% | +$2.29K |
|
345
Kymera Therapeutics
KYMR
$3.11B
| $125K | 0.06% |
2,640
+44
| +2% | +$2.08K |
|
346
Patterson-UTI
PTEN
$2.18B
| $125K | 0.06% |
16,313
+860
| +6% | +$6.58K |
|
347
Nurix Therapeutics
NRIX
$758M
| $124K | 0.06% |
5,512
+101
| +2% | +$2.27K |
|
348
Oric Pharmaceuticals
ORIC
$1.06B
| $123K | 0.06% |
11,997
+210
| +2% | +$2.15K |
|
349
Neumora Therapeutics
NMRA
$272M
| $122K | 0.06% |
9,261
+163
| +2% | +$2.15K |
|
350
Denali Therapeutics
DNLI
$2.26B
| $121K | 0.06% |
4,164
+72
| +2% | +$2.1K |
|